Hyaluronan as a drug pre-sensitizer and chemo-sensitizer in the treatment of disease
This application provides methods and compositions for the treatment of cancer. The application provides compositions comprising hyaluronic acid and a chemotherapeutic agent such as irinotecan that are useful in the treatment of cancer.
1. A method of treating cancer comprising intravenously administering to a subject in need thereof a therapeutically effective amount of hyaluronan prior to the administration of at least one cancer chemotherapeutic agent, wherein the hyaluronan is intravenously administered from 24 hours to 30 minutes prior to the intravenous administration of the cancer chemotherapeutic agent and wherein the hyaluronan has a size expressed as a molecular weight of 750,000 to 1,500,000 Daltons.
2. The method according to claim 1 wherein the hyaluronan has an intrinsic viscosity of 10.0 dl/gm to 14.5 dl/gm.
3. The method according to claim 2 wherein the modal molecular weight of hyaluronan is 750,000 Daltons.
4. The method according to claim 2 wherein the modal molecular weight of hyaluronan is 1,500,000 Daltons.
5. The method according to claim 1 wherein the cancer is selected from the group consisting of breast, lung, prostate, kidney, neural, ovary, uterus, liver, pancreas, epithelial, gastric, intestinal, exocrine, endocrine, lymphatic, haematopoetic system or head and neck tissue.
6. The method according to claim 1 wherein the subject is a mammal.
7. The method according to claim 6 wherein the mammal is selected from the group consisting of bovine, canine, equine, feline, porcine and human.
8. The method according to claim 1 in which the cancer chemotherapeutic agent is selected from the group consisting of carmustine (BCNU), cisplatin (Platinol), Cytarabine, doxorubicin (Adriamycin), 5-fluorouracil (5FU), methotrexate (mexate), irinotecan (CPT-11), etoposide, plicamycin (Mithracin) and taxanes.
9. The method according to claim 8 wherein the cancer chemotherapeutic agent is 5-fluorouracil.
10. The method according to claim 8 wherein the cancer chemotherapeutic agent is irinotecan.
11. The method according to claim 8 wherein the cancer chemotherapeutic agent is doxorubicin.
12. The method according to claim 1 wherein the hyaluronan is administered from 24 hours to 1 hour before the administration of the cancer chemotherapeutic agent.
13. The method of claim 1 wherein the hyaluronan is administered from 12 hours to 30 minutes before the cancer chemotherapeutic agent.
14. The method of claim 1 wherein the amount of hyaluronan in the composition is from 0.5 mg to 150 mg per kilogram body weight per day.
15. The method of claim 1 wherein the amount of hyaluronan in the composition is from 5 mg to 40 mg per kilogram body weight per day.
16. The method of claim 1 , wherein the wherein the modal molecular weight of hyaluronan is about 850,000 Daltons.